The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across
The post Exegenesis Bio receives US FDA clearance for EXG102-031 IND application appeared first on Pharmaceutical Business review.